Search results for "Venous Thromboembolism"
New studies assess effects of anticoagulation during, after COVID-19
Use of intermediate, full-dose, or prophylactic anticoagulation in COVID-19 inpatients wasn't associated with any difference in in-hospital mortality in one study, while another found it was safe to discontinue anticoagulation after three months in patients with a COVID-19-associated clot.
https://acphospitalist.acponline.org/archives/2022/11/16/free/new-studies-assess-effects-of-anticoagulation-during-after-covid-19.htm
16 Nov 2022
COVID-19 hospitalization carries higher VTE risk than flu regardless of vaccination status
The 90-day absolute risk of venous thromboembolism (VTE) was 5.3% in patients hospitalized with influenza compared to 9.5% in COVID-19 patients hospitalized before vaccine availability and 10.9% in patients with COVID-19 after vaccines became available, a study found.
https://acphospitalist.acponline.org/archives/2022/08/24/free/covid-19-hospitalization-carries-higher-vte-risk-than-flu-regardless-of-vaccination-status.htm
24 Aug 2022
Apixaban associated with less bleeding than warfarin for VTE in end-stage kidney disease
The use of apixaban among dialysis patients being treated for acute venous thromboembolism (VTE) rose from 2% in 2014 to 47% in 2018, according to an industry-funded retrospective comparison of the drug with warfarin.
https://acphospitalist.acponline.org/archives/2022/08/17/apixaban-associated-with-less-bleeding-than-warfarin.htm
17 Aug 2022
New guideline released on periop management of antithrombotic therapy
The American College of Chest Physicians issued 44 recommendations, covering use of vitamin K antagonists, heparin bridging, direct oral anticoagulants, and antiplatelet drugs in patients undergoing surgeries or procedures.
https://acphospitalist.acponline.org/archives/2022/08/17/free/new-guideline-released-on-periop-management-of-antithrombotic-therapy.htm
17 Aug 2022
Latest COVID-19 research looks at lung ultrasound, CVST and VTE risk, visitation policies
Recent studies offered a new method for using lung ultrasound to assess COVID-19 patients, assessed risk of central venous sinus thrombosis (CVST), and looked at a lab test to help predict venous thromboembolism (VTE) and at the effects of restricting visitors.
https://acphospitalist.acponline.org/archives/2022/08/10/free/latest-covid-19-research-looks-at-lung-ultrasound-cvst-and-vte-risk-visitation-policies.htm
10 Aug 2022
LMWH may offer best risk-benefit profile for thromboprophylaxis in medical inpatients
A meta-analysis found that an intermediate dose of low-molecular-weight heparin (LMWH) had the most favorable balance of risk and harms during hospitalization for acute illness, while unfractionated heparin and direct oral anticoagulants had the least.
https://acphospitalist.acponline.org/archives/2022/07/13/lmwh-may-offer-best-risk-benefit-profile-for-thromboprophylaxis-in-medical-inpatients.htm
13 Jul 2022
SHM selected new Choosing Wisely recommendations with patient input
The latest advice from the Society of Hospital Medicine (SHM) on avoiding low-value care includes recommendations against waking patients at night for routine care and against routinely prescribing venous thromboembolism prophylaxis to all inpatients.
https://acphospitalist.acponline.org/archives/2022/06/15/free/shm-selected-new-choosing-wisely-recommendations-with-patient-input.htm
15 Jun 2022
Tips on taking transfers from surgery
Talk directly to the surgeon, peek at the wound, and don't be afraid to call with questions, experts advised.
https://acphospitalist.acponline.org/archives/2022/05/11/free/tips-on-taking-transfers-from-surgery.htm
11 May 2022
Continuing aspirin for no reason?
A speaker made the case for anticoagulant monotherapy in selected patients with stable coronary artery disease and atrial fibrillation during a “Things We Do For No Reason” session at SHM Converge 2022.
https://acphospitalist.acponline.org/archives/2022/04/27/continuing-aspirin-for-no-reason.htm
27 Apr 2022
OPAT has similar safety, lower costs versus inpatient antibiotic therapy
Patients receiving outpatient parenteral antimicrobial therapy (OPAT) after hospitalization for bacterial infection had 90-day adverse event rates of 35.6% compared to 39.0% in those who stayed in the hospital for parenteral antimicrobial therapy, a retrospective Canadian study found.
https://acphospitalist.acponline.org/archives/2022/04/27/opat-has-similar-safety-lower-costs-versus-inpatient-antibiotic-therapy.htm
27 Apr 2022